Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eduardo Almeida-Gutiérrez has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between Venous Excess Ultrasound (VExUS) Score and Serum CA-125 Levels in Patients with Heart Failure and Left Ventricular Systolic Dysfunction: A Prospective Pilot Study

    by Louis Fernando Robles-Fernandes, Gabriela Rodríguez-Guzmán, Genaro Hiram Mendoza-Zavala, Eduardo Almeida-Gutierrez, Karina Lupercio-Mora, Diana Romero-Zertuche, Rosalba Carolina García-Méndez, Jesús Salgado-Campos, Amor Yanira Cazares-Avendaño, Juan Betuel Ivey-Miranda

    Introduction: Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Accurate assessment of congestion is fundamental in patients with worsening HF, yet physical examination and chest radiography may underestimate its severity. Carbohydrate antigen 125 (CA-125) has emerged as a biomarker associated with congestion severity and prognosis in HF. However, its relationship with ultrasound-defined systemic venous congestion using the Venous Excess Ultrasound (VExUS) score has not been evaluated. Material and methods: We conducted a prospective, cross-sectional, single-center pilot study including ambulatory patients with previously diagnosed chronic HF with reduced ejection fraction and with clinical suspicion of worsening heart failure. At inclusion, blood samples were obtained for CA-125 measurement and transthoracic echocardiography with VExUS assessment was performed during the same visit, prior to treatment adjustment. The primary objective was to determine the association between VExUS score and CA-125 levels. Results: Fifty-four patients were included. A moderate positive correlation was observed between VExUS grade and CA-125 (Spearman ρ=0.46, p<0.001). In multivariable analysis adjusting for age, ejection fraction and serum creatinine, VExUS grade remained independently associated with CA-125 (β = 0.387, p = 0.001). Discussion: In patients with HF and left ventricular systolic dysfunction, CA-125 levels correlate with ultrasound-defined systemic venous congestion. CA-125 may represent an accessible biomarker reflecting congestion severity in ambulatory clinical settings.


  • Open Access

    [Pharmacological adherence and cardiometabolic goals in successfully reperfused acute myocardial infarction].

    by Carlo Alberto Fabela-Hardy, Luis Antonio Moreno-Ruiz, Yatzil Necoechea-Osuna, Diana Romero-Zertuche, Eduardo Almeida-Gutiérrez, Karina Lupercio-Mora, Luis Efrén Santos-Martínez

    Adherence to treatment in the secondary prevention of ST-elevation myocardial infarction (STEMI) improves survival and quality of life. To measure treatment adherence and its association with the frequency of achievement of cardiometabolic targets in patients with STEMI. A total of 157 adults with STEMI < 12 hours, with successful reperfusion, and in phase 3 of cardiac rehabilitation were included. Demographic variables were collected, and adherence as well as achievement of cardiometabolic targets were measured. Univariate, bivariate (chi-square, Student's t test, or Mann-Whitney U test, depending on distribution), and multivariate logistic regression analyses were performed (p < 0.05). Adherence was 75%, with a higher percentage of patients meeting LDL cholesterol (54% vs. 21%, p < 0.001), triglyceride (79% vs. 46%, p < 0.001), and glycated hemoglobin (63% vs. 23%, p < 0.001) targets compared to the non-adherent group. Adherence was an independent factor for achieving cardiometabolic targets, with an odds ratio (OR) of 9.8 (95% confidence interval [95% CI]: 3.6-16.3; p < 0.001). Treatment adherence was associated with a higher frequency of achievement of cardiometabolic targets.

  • Open Access

    Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications

    by Mardia López-Alarcón, Víctor Saúl Vital-Reyes, Eduardo Almeida-Gutiérrez, Jorge Maldonado-Hernández, Salvador Flores-Chávez, Juan Manuel Domínguez-Salgado, José Vite-Bautista, David Cruz-Martínez, Aly S. Barradas-Vázquez, Ricardo Z’cruz-López

    Polycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without PCOS were evaluated. The clinical biomarkers of alterations related to glucose (glucose, insulin, and clamp-derived glucose disposal − M), liver (aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase), and endothelium (arginine, asymmetric dymethylarginine, carotid intima-media thickness, and flow-mediated dilation) metabolism were measured; participants were categorized into four groups according to their obesity (OB) and hyperandrogenemia (HA) status as follows: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were very frequent in women with PCOS (≈70%). BMI correlated with all biomarkers, whereas free testosterone (FT) correlated with only glucose- and liver-related indicators. Although insulin sensitivity and liver enzymes were associated with FT, women with obesity showed lower M (coef = 8.56 − 0.080(FT) − 3.71(Ob); p < 0.001) and higher aspartate aminotransferase (coef = 26.27 + 0.532 (FT) + 8.08 (Ob); p = 0.015) than lean women with the same level of FT. Women with obesity showed a higher risk of metabolic disorders than lean women, independent of hyperandrogenemia. Clinicians are compelled to look for metabolic alterations in women with PCOS. Obesity should be treated in all cases, but hyperandrogenemia should also be monitored in those with glucose-or liver-related disturbances.


  • Open Access

    The Contribution of Obesity and Hyperandrogenemia to the Risk of Metabolic Disturbances of Women with Polycystic Ovary Syndrome Defines the Therapeutic Approach. Clinical Implications

    by Mardia López-Alarcón, Víctor Saul Vital-Reyes, Eduardo Almeida-Gutiérrez, Jorge Maldonado-Hernández, Salvador Flores-Chavez, Juan Manuel Dominguez-Salgado, Jose Vite-Bautista, David Cruz-Martinez, Aly S Barradas-Vazquez, Ricardo Z´cruz-Lopez

    Polycystic ovary syndrome (PCOS) usually comes along with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is frequently not investigated. We evaluated 99 PCOS and 41 non-PCOS women. Clinical biomarkers of glucose-, liver-, and endothelial-related metabolic alterations were measured; participants were categorized into four groups according with obesity (OB) and hyperandrogenemia (HA) statuses: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were highly frequent in PCOS women (70%). BMI correlated with all biomarkers, while free testosterone (FT) only with glucose- and hepatic-related indicators. Despite insulin sensitivity and liver enzymes were associated with FT, women with obesity exhibited lower M [coeff = 8.56 – 0.080(FT) –3.71(Ob); p <0.001)] and higher aspartate aminotransferase (coeff = 26.27 + 0.532(FT) + 8.08(Ob); p = 0.015)] than lean at the same level of FT. Women with obesity exhibited greater risk of metabolic disorders than lean, independently of hyperandrogenemia. Clinicians are compelled to search for metabolic alterations in PCOS women; obesity must be handled in all cases, but hyperandrogenemia needs to be managed also in those with glucose- or liver-related disturbances.

  • Open Access

    Calidad de la información de los promocionales de la industria farmacéutica y la educación médica

    by Luis Peredo-Silva, Hortensia Reyes-Morales, Luis Alberto Guizar-García, Eduardo Almeida-Gutiérrez, Ricardo Páez-Moreno, Alberto Lifshitz, Dolores Mino-León

    Introducción: El 15% de los promocionales de la industria farmacéutica (IF) incluyen información que no se fundamenta con los resultados del artículo original. Objetivo: Evaluar la validez de los artículos científicos originales que sustentan la información de los promocionales de la IF dirigidos a internistas y cardiólogos y conciliar la información del artículo científico original con la del promocional. Método: Los promocionales se obtuvieron en los congresos nacionales de Medicina Interna (MI) y Cardiología (C) realizados en México; aleatoriamente se seleccionaron 10 de cada especialidad; tres investigadores evaluaron la calidad de las referencias bibliográficas, la validez de los artículos originales y realizaron la conciliación de la información. Se realizó análisis descriptivo. Resultados: Se recolectaron 57 promocionales de MI y 16 de C; la calidad de las referencias bibliográficas de 4 promocionales de MI se evaluaron como evidencia “moderada” y las referencias de 4 promocionales de C como evidencia “no científica”. Los ensayos clínicos controlados de MI y C fueron válidos, un estudio observacional de C se catalogó sin validez. La conciliación de la información del promocional con la del artículo original reveló diferencias en cuatro promocionales de cada especialidad y de acuerdo con los criterios éticos para la promoción de medicamentos de la Organización Mundial de la Salud (OMS) predominó la falta de exactitud, en algunos casos la información no fue fidedigna y/o verdadera. Conclusiones: Es importante capacitar al médico en lectura crítica, para que evalúe objetivamente la información e identifique la promoción de medicamentos inefectivos y/o inseguros.

  • Open Access

    Failures of the Fontan System in Univentricular Hearts and Mortality Risk in Heart Transplantation: A Systematic Review and Meta-Analysis

    by Horacio Márquez-González, Jose Gustavo Hernández-Vásquez, Montserrat Del Valle-Lom, Lucelli Yáñez-Gutiérrez, Miguel Klünder-Klünder, Eduardo Almeida-Gutiérrez, Solange Gabriela Koretzky

    The Fontan procedure (FP) is the standard surgical treatment for Univentricular heart diseases. Over time, the Fontan system fails, leading to pathologies such as protein-losing enteropathy (PLE), plastic bronchitis (PB), and heart failure (HF). FP should be considered as a transitional step to the final treatment: heart transplantation (HT). This systematic review and meta-analysis aims to establish the risk of death following HT according to the presence of FP complications. There was a total of 691 transplanted patients in the 18 articles, immediate survival 88% (n = 448), survival from 1 to 5 years of 78% (n = 427) and survival from 5.1 to 10 years of 69% (n = 208), >10 years 61% (n = 109). The relative risk (RR) was 1.12 for PLE (95% confidence interval [CI] = 0.89–1.40, p = 0.34), 1.03 for HF (0.7–1.51, p = 0.88), 0.70 for Arrhythmias (0.39–1.24, p = 0.22), 0.46 for PB (0.08–2.72, p = 0.39), and 5.81 for CKD (1.70–19.88, p = 0.005). In patients with two or more failures, the RR was 1.94 (0.99–3.81, p = 0.05). After FP, the risk of death after HT is associated with CKD and with the presence of two or more failures.


  • Assessment of right atrial pressure with two-dimensional, Doppler and speckle tracking echocardiography in patients with acute right ventricular myocardial infarction.

    by J.B. Ivey-Miranda, E.L. Posada-Martínez, E. Almeida-Gutierrez, E. Flores-Umanzor, G. Borrayo-Sanchez, G. Saturno-Chiu


  • Right ventricular longitudinal strain predicts acute kidney injury and short-term prognosis in patients with right ventricular myocardial infarction

    by Juan Betuel Ivey-Miranda, Eduardo Almeida-Gutiérrez, Gabriela Borrayo-Sánchez, Javier Antezana-Castro, Alicia Contreras-Rodríguez, Edith Liliana Posada-Martínez, Edith González-Morales, Nayeli García-Hernández, Diana Romero-Zertuche, Horacio Marquez-Gonzalez, et al.

    Right ventricular (RV) systolic dysfunction due to acute myocardial infarction is associated with serious complications in the short-term. Acute kidney injury (AKI) is a frequent and unrecognized complication. This study aimed to assess whether RV longitudinal strain predicts AKI and short-term prognosis in patients with RV infarction. Prospective cohort of patients with RV infarction. RV function was evaluated with global and free wall right ventricular longitudinal strain (GRVLS and FWRVLS), tricuspid annular plane systolic excursion, and tricuspid S′ wave. The primary endpoint was AKI defined as an increase ≥ 50% in serum creatinine and/or a decrease ≥ 25% in glomerular filtration rate during follow-up at 7 days. The secondary endpoint was death from any cause at 30 days. We included 101 patients with RV infarction (male 67%, age 66 ± 11 years). During follow-up at 7 days, 40% of patients developed AKI. At 30 days, 8% of patients died. At univariate analysis, FWRVLS was significantly associated with AKI (Hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.03–1.20, p = 0.006). At multivariate analysis, only age, temporary pacemaker implant, and FWRVLS remained as independent predictors of AKI (HR 1.05, 95% CI 1.02–1.08, p = 0.002; HR 2.12, 95% CI 1.11–4.07, p = 0.023; HR 1.10, 95% CI 1.02–1.19, p = 0.018, respectively). At 30 days, patients with FWRVLS ≥ − 15.5% showed a lower survival rate than those with lower strain (84 ± 6 vs. 97 ± 2%, p = 0.021). In patients with RV infarction, FWRVLS was an independent predictor of AKI and was associated with higher mortality in the short-term.


  • Right atrial pressure predicts worsening renal function in patients with acute right ventricular myocardial infarction

    by Juan Betuel Ivey-Miranda, Edith Liliana Posada-Martínez, Eduardo Almeida-Gutiérrez, Gabriela Borrayo-Sánchez, Eduardo Flores-Umanzor


  • Open Access

    Tei Index Is the Best Echocardiographic Parameter for Assessing Right Ventricle Function in Patients With Unrepaired Congenital Heart Diseases With Outflow Tract Obstruction

    by Horacio Márquez-González, Mario H. Vargas, Lucelli Yáñez-Gutiérrez, Eduardo Almeida-Gutiérrez, Juan Garduño-Espinosa

    Objective: Magnetic resonance imaging (MRI) and cardiac catheterization are diagnostic tools for right ventricle dysfunction (RVD), but those are expensive and often unavailable techniques. Thus, our objective was to identify clinical and/or echocardiographic variables capable of predicting a catheterization-based diagnosis of RVD. Design: This was cross-sectional, diagnostic test accuracy study, considering the catheterization-based diagnosis of RVD as the gold standard. Patients: Pediatric patients with non-repaired CHD with overload pressure were evaluated. Clinical variables (edema and functional class), transthoracic echocardiography (right heart dimensions, systolic and diastolic function, Doppler velocities), and cardiac catheterization (pressures and right ventricle systolic work measurements) were obtained during the same hospitalization. Results: We included 253 patients with tetralogy of Fallot (39.9%), pulmonary atresia with ventricular septal defect (33.9%), type C Ebstein’s anomaly (15.8%), or pulmonary stenosis (10.4%). Among clinical (vascular congestion, functional class derangement) and echocardiographic (indexed right ventricle diameter, fractional area change, tricuspid annular plane systolic excursion, S’ wave, Tei index) variables, the Tei index (defined as the ratio of isovolumetric contraction time to ejection time) was the sole variable that exhibited high diagnostic capability, with 98.5% sensitivity, 97.4% specificity, 97.8% positive predictive value, and 98.3% negative predictive value, with 98.0% overall performance. Multivariate logistic regression confirmed that Tei index alone predicted the catheterization-based diagnosis of RVD. Conclusions: Tei index is the best parameter that can be employed for the non-invasive identification of RVD in patients with CHD.